Bulbar muscle weakness and fatty lingual infiltration in glycogen storage disorder type IIIa
Highlights
► We provide the first report of bulbar muscle involvement in glycogen storage disorder (GSD) IIIa. ► Three GSD IIIa patients had lingual weakness by instrumental assessment. ► One patient had correlative abnormal fatty infiltration of the tongue on MRI. ► Supportive abnormal glycogen infiltration on histopathology is seen in a canine model of GSD IIIa.
Introduction
Glycogen storage disorder type III (GSD III) is a rare autosomal recessive disorder that results from a deficiency of glycogen debranching enzyme (GDE), a critical enzyme in glycogen degradation [1]. There are 2 major GSD III subtypes, with GSD IIIa accounting for about 85% of affected individuals and GSD IIIb comprising approximately 15%. Patients with GSD IIIa have involvement of skeletal muscle, cardiac muscle, and liver, while GSD IIIb results primarily in hepatic disease [2]. GSD IIIa typically presents in early childhood with hepatomegaly, ketotic hypoglycemia, hypertriglycemia, and elevated liver transaminases. Myopathy is usually slowly progressive, with early weakness, hypermobility, and increased abdominal girth from hepatomegaly leading to delay in the achievement of gross motor skills in infancy [3]. These findings are generally followed by more pronounced muscle weakness in the third and fourth decades [4], [5] which may be exacerbated by underlying peripheral polyneuropathy [6], [7]. The proximal musculature is primarily affected, but distal muscle involvement may also be present in the calves, peroneal muscles [8], and hands [5], [9]. Cardiac involvement in the form of hypertrophy and cardiac rhythm disturbances has also been noted and usually emerges during childhood [10], [11]. Other disease features may include impaired growth, osteoporosis and osteopenia [12], and polycystic ovary disease [13].
Although skeletal muscle involvement occurs commonly in GSD IIIa, involvement of the bulbar muscles has not, to our knowledge, been previously reported. We have recently encountered bulbar disease in the form of lingual weakness in three patients with GSD IIIa. A proband patient led to the evaluation of lingual disease in two additional consecutive clinic patients with GSD IIIa, and we performed further correlation with lingual pathology from necropsy in a naturally-occurring canine model of GSD IIIa (detailed in a recent publication by Yi et al. [14]). We will describe the clinical findings in these three patients and the animal model.
Section snippets
Materials and methods
The three patients with GSD III were encountered via the GSD program at the Metabolic Clinic at Duke University Medical Center during routine clinical care. These data are presented as part of a larger Institutional Review Board-approved GSD III natural history study. GSD IIIa was confirmed with gene mutation analysis and/or enzymatic assay in all patients.
Standard physical examinations were performed which included manual muscle strength testing and assessment of gross motor function. Patients
Results
Table 1 summarizes the clinical characteristics of the 3 human patients presented in this study.
Discussion
While cardiac and skeletal muscle disease have been clearly established in GSD IIIa, bulbar muscle involvement has not been previously reported. We have provided the first description of bulbar muscle involvement in GSD IIIa, detailing three consecutive patients with instrumentally confirmed lingual weakness. Further supportive evidence was provided by MRI findings which revealed fatty infiltration at the base of the intrinsic tongue musculature and abnormal expansion of the fibro-fatty lingual
Acknowledgments
We thank Dr. Beth L. Thurberg at Genzyme Corporation for her contribution of the canine histopathology for this report. We also thank Dr. Baodong Sun at Duke University for his guidance and assistance with the GSD IIIa canine model.
References (25)
- et al.
Amylo-1, 6-glucosidase in muscle tissue in generalized glycogen storage disease
J. Biol. Chem.
(1956) Glycogen storage disease type III diagnosis and management guidelines
Genet. Med.
(2010)The electrodiagnostic characteristics of Glycogen Storage Disease Type III
Genet. Med.
(2010)Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time
Genet. Med.
(2010)Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns
Neuromuscul. Disord.
(2011)The effects of lingual exercise in stroke patients with dysphagia
Arch. Phys. Med. Rehabil.
(2007)- et al.
Utility of a urinary tetrasaccharide as a biomarker for glycogen storage disease type III
Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features
J. Inherit. Metab. Dis.
(1992)- et al.
Glycogen Storage Disease Type III
Different clinical aspects of debrancher deficiency myopathy
J. Neurol. Neurosurg. Psychiatry
(1999)
Liver glycogenoses: are they a possible cause of polyneuropathy? A cross-sectional study
J. Trop. Pediatr.
Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency
Acta Myol.
Cited by (7)
A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme
2020, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :In some cases, cardiomyopathy can lead to heart failure and sudden death.4,7,13 Bulbar muscle weakness was seen in some GSD IIIa patients.14 To date, there is no cure for GSD III.
Glycogen storage disease type III: A novel Agl knockout mouse model
2014, Biochimica et Biophysica Acta - Molecular Basis of DiseaseCitation Excerpt :As shown in Supplementary Fig. 2, nerve tissue had a normal appearance and no glycogen granules were detected. Since a recent clinical study observed fatty infiltration in the tongue musculature in some GSDIII patients [19], we analyzed tongue tissue from 4- and 18-mo-old mice. In Agl-KO mice, we found glycogen accumulation, as shown in Supplementary Fig. 3.
Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects
2021, Journal of Inherited Metabolic DiseaseOral manifestations in patients with glycogen storage disease: A systematic review of the literature
2020, Applied Sciences (Switzerland)Update review about metabolic myopathies
2020, LifeWhole-Body Muscle Magnetic Resonance Imaging in Glycogen-Storage Disease Type III
2019, Muscle and Nerve